Mark Eisner Sells 1,889 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 1,889 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $9.82, for a total transaction of $18,549.98. Following the completion of the sale, the executive vice president directly owned 154,024 shares in the company, valued at approximately $1,512,515.68. The trade was a 1.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Mark Eisner also recently made the following trade(s):

• On Tuesday, February 24th, Mark Eisner sold 1,616 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.53, for a total value of $15,400.48.
• On Monday, February 23rd, Mark Eisner sold 2,089 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total value of $15,563.05.

Vir Biotechnology Stock Down 2.5%

NASDAQ:VIR opened at $9.09 on Friday. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $10.94. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -2.88 and a beta of 1.69. The stock’s 50 day moving average price is $7.01 and its two-hundred day moving average price is $6.07.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. During the same period in the previous year, the firm earned ($0.76) EPS. The firm’s revenue was up 417.8% compared to the same quarter last year. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analysts Set New Price Targets

VIR has been the subject of a number of research reports. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price for the company in a research note on Tuesday. Needham & Company LLC increased their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Evercore restated an “outperform” rating and set a $18.00 price objective on shares of Vir Biotechnology in a report on Tuesday. Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $19.89.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

Institutional Investors Weigh In On Vir Biotechnology

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its holdings in Vir Biotechnology by 2,088.4% in the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after acquiring an additional 256,037 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Vir Biotechnology in the first quarter worth $359,000. Goldman Sachs Group Inc. raised its stake in Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Woodline Partners LP raised its stake in Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after purchasing an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth lifted its position in Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after purchasing an additional 2,566 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.